Heart Pump Devices Market Accelerates Toward USD 23.2 Billion by 2036
August 26, 2026 — The global heart
pump devices market was valued at USD 4.8 billion in 2025, is estimated
at USD 5.5 billion
in 2026, and is projected to reach USD 23.2 billion by 2036,
expanding at a 15.4%
CAGR from 2026 to 2036, according Fact.MR’s Analysis. The
forecast represents absolute growth of USD 17.7 billion over the period.
Demand
is moving beyond temporary mechanical support toward broader use of durable
heart pumps and destination therapy. Fact.MR attributes growth to aging
populations, rising cases of ischemic cardiomyopathy linked to diabetes and
hypertension, and advances in fully magnetically levitated pumps.
Continuous-flow LVADs are also showing improved clinical outcomes, with
five-year survival close to 60%, according to the report.
Get detailed market forecasts, competitive benchmarking, and
pricing trends: https://www.factmr.com/connectus/sample?flag=S&rep_id=14331
Clinical and Regulatory Evidence Supports Adoption
Several
dated sources cited by Fact.MR support the market's expansion. In October 2022,
the Centers for
Medicare & Medicaid Services (CMS) revised National
Coverage Determination 20.9.1 to expand Medicare destination-therapy coverage
to include INTERMACS Profile 3 patients.
In November 2019,
the New England
Journal of Medicine published results from the MOMENTUM 3
trial. The study reported 86%
freedom from disabling stroke or device failure at two years for
the relevant HeartMate 3 comparison, as cited by Fact.MR.
Fact.MR
also cites a 2024
American Heart Association scientific statement, reporting
that 75% of
HeartMate 3 patients were discharged within two weeks. In
addition, Abbott reported USD
480 million in HeartMate 3 sales in 2024, representing
roughly 1,600
implants, according to the report.
Key Numbers
·
Market value, 2025 — USD 4.8 billion
·
Market value, 2026 — USD 5.5 billion
·
Forecast value, 2036 — USD 23.2 billion
·
CAGR, 2026–2036 — 4%
·
Absolute growth — USD 17.7 billion
·
Implanted devices share, 2026 — 3%
·
LVAD share of VAD segment, 2026 — 1%
·
Hospital share — 2%
Source: Fact.MR analysis.
Segment Breakdown
By type, implanted heart pump devices lead with 69.3% share in
2026. These systems can support patients beyond the hospital
setting. Fact.MR says implanted devices have durability ranging from three to
10 years, supporting their use in longer-term mechanical circulatory support.
By product, LVADs account for 70.1% of the VAD segment in 2026. The
report links this position to the prevalence of left ventricular dysfunction in
advanced heart failure. Temporary Impella systems remain important for
short-term stabilization, while total artificial hearts continue to face
regulatory limits for permanent use.
By end use, hospitals hold 84.2% share. VAD
implantation and ECMO cannulation require specialized operating rooms, cardiac
surgery capabilities, and related infrastructure.
Country CAGR Outlook
·
China — 7%
·
United States — 4%
·
United Kingdom — 0%
·
South Korea — 8%
·
Japan — 0%
Source: Fact.MR proprietary forecasting model
and primary research.
China
represents the fastest growth among the listed markets at 21.7% CAGR, supported
by expanding cardiac infrastructure, reimbursement initiatives, and domestic
LVAD development. The United States follows at 20.4%, supported by
regulatory and reimbursement infrastructure. The United Kingdom, South Korea,
and Japan are forecast to grow at 20.0%,
19.8%, and 18.0%, respectively.
Competitive Landscape
The
market is concentrated in durable implanted LVADs. Abbott Laboratories leads
the U.S. durable LVAD market with HeartMate 3 following Medtronic's HVAD
withdrawal. ABIOMED,
Inc., now under Johnson & Johnson, leads the temporary
percutaneous segment with Impella systems. Other companies profiled by Fact.MR
include CorWave SA,
LivaNova PLC, Berlin Heart GmbH, SynCardia Systems LLC, Jarvik Heart, Inc.,
BiVACOR Inc., and Medtronic plc.
Fact.MR
does not disclose individual
company market-share percentages on the supplied page, so no
company share is assigned here. The disclosed segment shares are 69.3% for implanted devices, 70.1% for
LVADs within the VAD segment, and 84.2% for hospitals.
Analyst View
Shambhu
Nath Jha, Principal Consultant at Fact.MR, states that regulatory movement
toward destination therapy is reshaping commercial strategy, while device
miniaturization and full magnetic levitation technologies are expanding the
addressable patient population toward earlier-stage candidates.
Frequently Asked Questions
How large is the heart pump devices market in 2025?
Fact.MR valued the market at USD
4.8 billion in 2025.
What will the heart pump devices market be worth in 2036?
The market is projected to reach USD
23.2 billion by 2036.
What is the CAGR of the heart pump devices market?
Fact.MR forecasts a 15.4%
CAGR from 2026 to 2036.
Which heart pump device segment leads the market?
Implanted heart pump devices hold the largest type share at 69.3% in 2026.
Which country has the fastest forecast growth?
China leads the listed countries at 21.7%
CAGR through 2036.
Top Report
https://social.mytamam.com/blogs/33895/Agricultural-Biologicals-Market-to-Hit-USD-25-61-Billion-by
https://net-pals.com/blogs/25579/Agricultural-Biologicals-Market-to-Reach-USD-25-61-Billion-by
https://uddokta64.com/blogs/5562/Agricultural-Biologicals-Market-Set-to-Reach-USD-25-61-Billion
About Fact.MR
Fact.MR
is a market research and consulting firm providing market intelligence,
forecasts, competitive analysis, and strategic insights across healthcare,
technology, industrial, automotive, consumer, and other sectors. Its research
combines primary interviews, secondary research, market modeling, and data
validation.